This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Esomeprazole magnesium

Read time: 1 mins
Marketing start date: 26 Nov 2024
...
 

Summary of product characteristics


Effective Time

20230921

Version

4

Spl Product Data Elements

esomeprazole magnesium esomeprazole magnesium ESOMEPRAZOLE MAGNESIUM DIHYDRATE ESOMEPRAZOLE ALCOHOL AMMONIA BUTYL ALCOHOL FD&C BLUE NO. 1 FD&C RED NO. 3 FERROSOFERRIC OXIDE GELATIN GLYCERYL CAPRYLOCAPRATE HYDROXYPROPYL CELLULOSE (90000 WAMW) ISOPROPYL ALCOHOL MAGNESIUM OXIDE MAGNESIUM STEARATE MANNITOL METHACRYLIC ACID POLYSORBATE 80 POTASSIUM HYDROXIDE POVIDONE K30 PROPYLENE GLYCOL SHELLAC SODIUM LAURYL SULFATE STARCH, CORN SUCROSE TALC TITANIUM DIOXIDE TRIETHYL CITRATE WATER DARK BLUE OPAQUE (CAP) WHITE OPAQUE (BODY) CAPSULE 441;20mg esomeprazole magnesium esomeprazole magnesium ESOMEPRAZOLE MAGNESIUM DIHYDRATE ESOMEPRAZOLE ALCOHOL AMMONIA BUTYL ALCOHOL D&C RED NO. 28 FD&C BLUE NO. 1 FERROSOFERRIC OXIDE GELATIN GLYCERYL CAPRYLOCAPRATE HYDROXYPROPYL CELLULOSE (90000 WAMW) ISOPROPYL ALCOHOL MAGNESIUM OXIDE MAGNESIUM STEARATE MANNITOL METHACRYLIC ACID POLYSORBATE 80 POTASSIUM HYDROXIDE POVIDONE K30 PROPYLENE GLYCOL SHELLAC SODIUM LAURYL SULFATE STARCH, CORN SUCROSE TALC TITANIUM DIOXIDE TRIETHYL CITRATE WATER BLUE OPAQUE (CAP) OPAQUE WHITE (BODY) CAPSULE 442;40mg

Application Number

ANDA206296

Brand Name

Esomeprazole magnesium

Generic Name

esomeprazole magnesium

Product Ndc

70771-1493

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1493-3 Esomeprazole Magnesium Delayed-release Capsules, USP 20 mg 30 Capsules NDC 70771-1494-3 Esomeprazole Magnesium Delayed-release Capsules, USP 40 mg 30 Capsules 20 mg 30s label 40 mg 30s label

Spl Medguide

SPL MEDGUIDE

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.